Successful treatment of multiple filiform facial warts with imiquimod 5% cream in a patient infected by human immunodeficiency virus

Clin Exp Dermatol. 2003 May;28(3):260-1. doi: 10.1046/j.1365-2230.2003.01213.x.

Abstract

Imiquimod, an imidazoquinoline amine, is approved for the topical treatment of external anogenital warts induced by human papilloma virus. Several clinical trials have shown imiquimod to be an effective and safe drug for treatment of anogenital warts. Consequently, it was considered that imiquimod might be effective on warts caused by the same aetiological agent located on other skin areas. We describe the favourable outcome of a case of multiple facial verrucae in a human immunodeficiency virus (HIV)-infected patient treated with imiquimod 5% cream. This is a promising finding which supports those of two previous reports. We feel that imiquimod could be used in HIV-infected patients with multiple facial warts in whom conventional therapies are ineffective or produce significant side-effects.

Publication types

  • Case Reports

MeSH terms

  • AIDS-Related Opportunistic Infections / drug therapy*
  • AIDS-Related Opportunistic Infections / pathology
  • Adult
  • Aminoquinolines / therapeutic use*
  • Antiviral Agents / therapeutic use
  • Facial Dermatoses / drug therapy*
  • Facial Dermatoses / pathology
  • Humans
  • Imiquimod
  • Interferon Inducers / therapeutic use*
  • Male
  • Warts / drug therapy*
  • Warts / pathology

Substances

  • Aminoquinolines
  • Antiviral Agents
  • Interferon Inducers
  • Imiquimod